Greenwich LifeSciences Reports Sharply Increased Q1 Losses and Cash Burn, Raises $9.3M via ATM

summarizeSummary

Greenwich LifeSciences reported a substantial increase in Q1 net losses and cash burn, while reiterating its going concern warning and internal control weaknesses, despite raising $9.3 million through ATM offerings.

check_boxKey Events

• Accelerated Financial Deterioration

  Net loss more than doubled to $5.7 million, and cash used in operating activities more than doubled to $4.7 million for Q1 2026 compared to Q1 2025, indicating a rapidly increasing burn rate.

• Ongoing Going Concern Warning

  The company continues to report substantial doubt about its ability to continue as a going concern within one year, a reiteration of the warning from the recent 10-K.

• Persistent Material Weaknesses

  Disclosure controls and internal controls over financial reporting remain ineffective due to inadequate segregation of duties and insufficient policies, echoing disclosures from the recent 10-K.

• Significant Capital Raise via ATM

  Greenwich LifeSciences raised $9.03 million in net proceeds through At-The-Market (ATM) offerings in Q1 2026 and an additional $0.31 million in early Q2 2026, bringing the cash balance to $10.5 million as of March 31, 2026.

auto_awesomeAnalysis

This quarterly report highlights a significant deterioration in Greenwich LifeSciences' operational performance, with net losses and cash burn more than doubling in Q1 2026 compared to the prior year. The company continues to operate under a going concern warning and persistent material weaknesses in internal controls, underscoring fundamental risks. While a $9.3 million capital raise through ATM offerings has boosted the cash balance, it is a necessary measure to fund accelerating clinical trial expenses and extend the company's limited cash runway.